Cargando…
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119221/ https://www.ncbi.nlm.nih.gov/pubmed/34789825 http://dx.doi.org/10.1038/s41375-021-01473-1 |
| _version_ | 1784710658708733952 |
|---|---|
| author | Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel |
| author_facet | Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel |
| author_sort | Sekeres, Mikkael A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9119221 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91192212022-05-20 Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel Leukemia Correction Nature Publishing Group UK 2021-11-17 2021 /pmc/articles/PMC9119221/ /pubmed/34789825 http://dx.doi.org/10.1038/s41375-021-01473-1 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correction Sekeres, Mikkael A. Watts, Justin Radinoff, Atanas Sangerman, Montserrat Arnan Cerrano, Marco Lopez, Patricia Font Zeidner, Joshua F. Campelo, Maria Diez Graux, Carlos Liesveld, Jane Selleslag, Dominik Tzvetkov, Nikolay Fram, Robert J. Zhao, Dan Bell, Jill Friedlander, Sharon Faller, Douglas V. Adès, Lionel Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title | Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_full | Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_fullStr | Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_full_unstemmed | Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_short | Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML |
| title_sort | correction to: randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk mds/cmml or low-blast aml |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119221/ https://www.ncbi.nlm.nih.gov/pubmed/34789825 http://dx.doi.org/10.1038/s41375-021-01473-1 |
| work_keys_str_mv | AT sekeresmikkaela correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT wattsjustin correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT radinoffatanas correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT sangermanmontserratarnan correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT cerranomarco correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT lopezpatriciafont correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT zeidnerjoshuaf correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT campelomariadiez correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT grauxcarlos correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT liesveldjane correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT selleslagdominik correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT tzvetkovnikolay correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT framrobertj correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT zhaodan correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT belljill correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT friedlandersharon correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT fallerdouglasv correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml AT adeslionel correctiontorandomizedphase2trialofpevonedistatplusazacitidineversusazacitidineforhigherriskmdscmmlorlowblastaml |